



Regulated information



## Disclosure of acquisition of treasury shares

Waregem (Belgium) / Rotterdam (Netherlands)\*, 7 June 2010 - Arseus discloses the information with respect to the acquisition of treasury shares required under the new Article 207 of the Royal Decree of 30 January 2001 implementing the Belgian Company Code.

Arseus today announces that during the period from 28 May to 7 June, it acquired 34,177 treasury shares on NYSE Euronext Brussels.

Acquisition date	Number of shares	Average price	Lowest price	Highest price	Amount
28 May 2010	5,820	€ 8.8813	€ 8.74	€ 8.99	€ 51,689
31 May 2010	3,000	€ 8.8990	€ 8.80	€ 8.95	€ 26,697
1 June 2010	7,265	€ 8.9476	€ 8.80	€ 9.03	€ 65,004
2 June 2010	4,700	€ 9.0612	€ 8.87	€ 9.12	€ 42,588
3 June 2010	2,927	€ 9.1823	€ 9.12	€ 9.20	€ 26,877
4 June 2010	6,770	€ 9.2410	€ 9.08	€ 9.30	€ 62,562
7 June 2010	3,695	€ 9.1471	€ 9.05	€ 9.21	€ 33,799

The Extraordinary Shareholders' Meeting held on 16 June 2009 renewed the authorisation of the Board of Directors to acquire treasury shares.

### For more information:

Constantijn van Rietschoten

Director Corporate Communications

+31 88 33 11 222 (Office)

+31 6 536 91 585 (Mobile)

[constantijn.van.rietschoten@arseus.com](mailto:constantijn.van.rietschoten@arseus.com)

### Arseus profile

Arseus is a multinational group of companies that supplies products, services and concepts to professionals and institutions in the European healthcare sector. Arseus is subdivided into four divisions and operates in the markets for pharmaceutical compounding for pharmacies, dental products, medical and surgical products, and medical IT-solutions. The Belgian company Arseus NV is located in Waregem, and is listed on NYSE Euronext Brussels and NYSE Euronext Amsterdam. The operational activities of the Arseus group are driven by the Dutch company Arseus BV. The head office of Arseus BV is located in Rotterdam.

*In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.*

\* This press release was sent out by Arseus NV and Arseus BV.